Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | January 12, 2026 | March 03, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 54,876 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 54,876 · Balance 54,876 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
RIGEL PHARMACEUTICALS INC
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,125 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Sale · Disposed 2,500 · Balance 10,125 F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2: The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.
F2: The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aclaris Therapeutics, Inc.
Report date January 03, 2022 · Filed January 05, 2022
Section 16 reporting ended · disclosed 2022-01-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,214 |
Ending reported balance
After 2022-01-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-01-03 · Exercise / conversion · Acquired 3,875 · Balance 118,571 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 2 · 2022-01-03 · Exercise / conversion · Acquired 27,905 · Balance 146,476 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 3 · 2022-01-03 · Exercise / conversion · Acquired 6,638 · Balance 153,114 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 4 · 2022-01-03 · Exercise / conversion · Acquired 7,100 · Balance 160,214 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-03 · Exercise / conversion · Disposed 3,875 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-01-03 · Exercise / conversion · Disposed 27,905 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-01-03 · Exercise / conversion · Disposed 7,100 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F6: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-01-03 · Exercise / conversion · Disposed 6,638 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F5: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited.
F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F5: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F6: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 20:04 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 2,500 | $35.00 | $87,500.00 |
DisclosureSEC source: 0000905148-26-003076 · form4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,125 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2 · kind: The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:19 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 2,500 | $29.17 | $72,925.00 |
DisclosureSEC source: 0000905148-26-002724 · form4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,625 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. Read SEC document |
| May 15, 2026 Filed May 20, 2026 00:48 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002529 · form4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,125 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| January 12, 2026 Filed Mar 3, 2026 23:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 54,876 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001140361-26-007641 · form4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,876 Underlying: Common Stock · 54,876 shares Expires 2036-01-12 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 22:00 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,700 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001140361-25-022225 · form4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 22,700 shares Expires 2035-06-11 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001935 · form4.xml · derivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2035-05-23 F3 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001935 · form4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,375 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. F2 · balance_after: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:05 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001140361-24-031289 · form4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:19 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0000905148-24-001651 · form4.xml · derivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-25 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:19 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001651 · form4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,750 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:28 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001140361-23-034836 · form4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001140361-23-034284 · form4.xml · derivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-034284 · form4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,750 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 20:15 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001140361-22-024466 · form4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001140361-22-020303 · form4.xml · derivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-20 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020303 · form4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 7,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001712 · doc4.xml · derivative · entry 8 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Unit · Derivative | 6,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001712 · doc4.xml · derivative · entry 7 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,914 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 27,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001712 · doc4.xml · derivative · entry 6 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001712 · doc4.xml · derivative · entry 5 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-001712 · doc4.xml · nonDerivative · entry 4 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 6,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-001712 · doc4.xml · nonDerivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 27,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-001712 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-001712 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 21:22 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001567619-21-022261 · doc1.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-12-16 F1 · derivative.exercise_date: The option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the Reporting Person was appointed to the Company's Board of Directors and ending on the date of the annual meeting at which the Reporting Person is first considered for election by the stockholders, provided that the Reporting Person continues to provide service. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 23:09 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001140361-21-021497 · form4.xml · derivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-17 F2 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on June 17, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:09 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 11,764 | $8.50 | $99,994.00 |
DisclosureSEC source: 0001140361-21-021497 · form4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,764 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:52 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 9,492 | $21.96 | $208,420.59 |
DisclosureSEC source: 0001209191-21-038442 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,196 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.57 to $22.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 01:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 2,387 | $22.31 | $53,256.83 |
DisclosureSEC source: 0001209191-21-037482 · doc4.xml · nonDerivative · entry 7 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,688 F7 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. F9 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.07 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 01:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 12,732 | $21.51 | $273,822.03 |
DisclosureSEC source: 0001209191-21-037482 · doc4.xml · nonDerivative · entry 6 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,075 F7 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. F8 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 01:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 2,517 | $22.32 | $56,173.15 |
DisclosureSEC source: 0001209191-21-037482 · doc4.xml · nonDerivative · entry 5 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,807 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 01:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 12,483 | $21.50 | $268,411.96 |
DisclosureSEC source: 0001209191-21-037482 · doc4.xml · nonDerivative · entry 4 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,324 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.03 to $22.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 01:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 33,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037482 · doc4.xml · derivative · entry 8 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,189 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F10 · derivative.exercise_date: The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020. F10 · derivative.expiration_date: The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 01:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 5,254 | $23.57 | $123,851.49 |
DisclosureSEC source: 0001209191-21-037482 · doc4.xml · nonDerivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,807 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.27 to $23.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 01:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 9,746 | $22.72 | $221,447.64 |
DisclosureSEC source: 0001209191-21-037482 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,061 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.25 to $23.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 01:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 33,189 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037482 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| May 07, 2021 Filed May 7, 2021 22:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,416 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-21-031038 · doc4.xml · derivative · entry 8 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,416 shares Expires 2025-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 07, 2021 Filed May 7, 2021 22:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 2,100 | $23.99 | $50,376.06 |
DisclosureSEC source: 0001209191-21-031038 · doc4.xml · nonDerivative · entry 6 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,618 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.83 to $24.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2021 Filed May 7, 2021 22:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 3,316 | $23.23 | $77,015.76 |
DisclosureSEC source: 0001209191-21-031038 · doc4.xml · nonDerivative · entry 5 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,718 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.83 to $23.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2021 Filed May 7, 2021 22:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 5,416 | $10.66 | $57,734.56 |
DisclosureSEC source: 0001209191-21-031038 · doc4.xml · nonDerivative · entry 4 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-21-031038 · doc4.xml · derivative · entry 7 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 20,416 shares Expires 2025-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 3,102 | $23.86 | $74,015.58 |
DisclosureSEC source: 0001209191-21-031038 · doc4.xml · nonDerivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,618 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.79 to $23.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 11,898 | $23.32 | $277,437.56 |
DisclosureSEC source: 0001209191-21-031038 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,720 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.79 to $23.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2021 Filed May 7, 2021 22:28 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 15,000 | $10.66 | $159,900.00 |
DisclosureSEC source: 0001209191-21-031038 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · derivative · entry 12 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,416 Underlying: Common Stock · 35,416 shares Expires 2025-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 498 | $24.36 | $12,129.24 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 9 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,618 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F7 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.33 to $24.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 14,502 | $23.97 | $347,583.94 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 8 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,116 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.32 to $24.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 15,000 | $10.66 | $159,900.00 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 7 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · derivative · entry 11 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,416 Underlying: Common Stock · 50,416 shares Expires 2025-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 1,279 | $24.47 | $31,295.98 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 6 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,618 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.19 to $24.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.